CA2166913A1 - Quantitative detection of analytes on immunochromatographic strips - Google Patents
Quantitative detection of analytes on immunochromatographic stripsInfo
- Publication number
- CA2166913A1 CA2166913A1 CA002166913A CA2166913A CA2166913A1 CA 2166913 A1 CA2166913 A1 CA 2166913A1 CA 002166913 A CA002166913 A CA 002166913A CA 2166913 A CA2166913 A CA 2166913A CA 2166913 A1 CA2166913 A1 CA 2166913A1
- Authority
- CA
- Canada
- Prior art keywords
- analyte
- binding partner
- strip
- region
- labeled binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000001514 detection method Methods 0.000 title claims description 16
- 239000012491 analyte Substances 0.000 claims abstract description 82
- 230000027455 binding Effects 0.000 claims abstract description 49
- 238000009739 binding Methods 0.000 claims abstract description 49
- 238000012360 testing method Methods 0.000 claims abstract description 45
- 239000012530 fluid Substances 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 28
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 55
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 55
- 239000010931 gold Substances 0.000 claims description 26
- 229910052737 gold Inorganic materials 0.000 claims description 26
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 25
- 239000011159 matrix material Substances 0.000 claims description 24
- 230000009870 specific binding Effects 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 9
- 230000003100 immobilizing effect Effects 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 238000003317 immunochromatography Methods 0.000 abstract description 3
- 238000003556 assay Methods 0.000 abstract description 2
- 238000005065 mining Methods 0.000 abstract 1
- 238000001055 reflectance spectroscopy Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 23
- 230000000903 blocking effect Effects 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 239000012528 membrane Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000004033 plastic Substances 0.000 description 9
- 229920003023 plastic Polymers 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229920003094 Methocel™ K4M Polymers 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004699 Ultra-high molecular weight polyethylene Substances 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- OMFRMAHOUUJSGP-IRHGGOMRSA-N bifenthrin Chemical compound C1=CC=C(C=2C=CC=CC=2)C(C)=C1COC(=O)[C@@H]1[C@H](\C=C(/Cl)C(F)(F)F)C1(C)C OMFRMAHOUUJSGP-IRHGGOMRSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 229940102098 revolution Drugs 0.000 description 1
- 238000012206 semi-quantitative assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- BSYLOTSXNQZYFW-UHFFFAOYSA-K trichlorogold;hydrate Chemical compound O.Cl[Au](Cl)Cl BSYLOTSXNQZYFW-UHFFFAOYSA-K 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/805—Test papers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/97—Test strip or test slide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/81—Tube, bottle, or dipstick
Abstract
Disclosed is an improved method for determining the concentration of analyte in a test fluid by immunochroma-tography techniques which involves quantitatively deter-mining the signals from captured analyte/labeled binding partner complex by instrumental means, e.g. reflectance spectrometry. In a preferred embodiment, a reflectance reading is determined for the captured complex and uncom-plexed labeled binding partner which is captured in a separate zone of the immunochromatographic strip and the ratio of these reflectances is used to provide additional quantitation to the assay method.
Description
216691~
QUANTITATIVE DETECTION OF ANALYTES
ON IMMUNOCHROMATOGRAPHIC STRIPS
Background of the Invention Immunochromatographic strip formats are increasingly popular for qualitative and semi-quantitative assays which use visual detection schemes. This type of immuno-assay involves the application of a liquid test samplesuspected of containing an analyte to be detected to an application zone of an immunochromatographic test strip.
The strip is comprised of a matrix material through which the test fluid and analyte suspended or dissolved therein can flow by capillarity from the application zone to a detection zone where a visible signal, or absence of such, reveals the presence of the analyte. Typically, the strip will include means for immunospecifically bind-ing the analyte to be detected with its specific binding partner which bears a detectable label. In one such scheme; as disclosed in U.S. Patent 4,446,232; the strip contains an enzyme labeled, mobile binding partner for the analyte which is in a zone downstream from the sample application zone. If analyte is present in the test sam-ple, it will combine with its labeled binding partner toform a complex which will flow along the strip to a de-tection zone which contains a substrate for the enzyme label capable of providing a colored response in the presence of the enzyme label. The strip contains a zone in which analyte is immobilized, so that labeled binding partner which does not combine with analyte, due to ab-sence of analyte in the sample, will be captured and thereby inhibited from reaching the detection zone.
There have been published various modifications of this MSE #1884 technique, all of which involve some competitive specific binding system in which the presence or absence of ana-lyte in the test sample is determined by the detection or lack thereof of labeled binding partner in the detection zone. In U.S. Patent 4,868,108 there is disclosed a similar scheme with the addition of an immobilized cap-ture reagent for the enzyme labeled binding partner in the detection zone to concentrate the enzyme label and enhance its ability to react with the enzyme substrate and thereby render the assay more sensitive.
Not all of the schemes for immunochromatography rely on an enzyme labeled binding partner/enzyme substrate as providing the signal for detection of the analyte. In U.S. Patent 4,806,311 there is disclosed a multizone test device for the specific binding assay determination of an analyte and an immobilized binding partner the-efore to-gether with a detection zone for receiving labeled rea-gent which migrates thereto from the reagent zone. The detection zone contains an immobilized form of a binding substance for the labeled reagent. The labeled reagent bears a detectable chemical group having a detectable physical property which is detectable on the basis of its own physical properties, so that it does not require a chemical reaction with another substance. Exemplary of such groups are colored species fluorescers, phosphores-cent molecules, radioisotopes and electroactive moieties.
United States Patent 4,313,734 describes the use of gold sols as labels for antibodies which are detectable without a chemical change.
MSE #1884 Immunochromatographic strip formats provide a viable system for the determination of various analytes (whether they be antigens or antibodies) but suffer from the limi-tation that they yield results which are at best semi-quantitative when, for some analytes, a quantitative an-swer is required. Accordingly, it would be desirable and it is an object of the present invention to provide a means for quantifying the results of analyses carried out by the use of immunochromatographic strip formats.
Summary of the Invention The present invention involves an improvement to a method for determining an analyte in a test fluid which involves applying the test fluid to an immunochroma-tographic matrix which allows the test fluid; and the analyte, if present; to flow through the matrix by capil-larity and which matrix contains a labeled binding part-ner for the analyte. The matrix, which is normally in the form of a test strip, also contains at least one de-tection zone in which the presence or absence of the ana-lyte is determined by detecting the label carried by the specific binding partner. The improvement involves de-termining the concentration of the label using an instru-ment having a detector capable of determining its concen-tration in the detection zone(s).
In a preferred embodiment of the present invention there is provided a test strip comprising a strip having a first region which contains mobile specific binding partner for the analyte which bears a detectable label and can react with the analyte to form an analyte/labeled MSE #1884 binding partner complex and at least one second region which contains an immobilized analyte or analog thereof.
The term analog as used herein refers to any substance capable of being bound by the active site of the specific binding partner.
The strip as described above is developed by apply-ing the test fluid sample suspected of containing the analyte thereto thereby allowing it to contact the mo-bile, labeled specific binding partner for the analytewhereby analyte present in the fluid test sample binds to the labeled specific binding partner to form the complex;
leaving excess, unreacted labeled binding partner free to further react whereby the fluid test sample carries the analyte~labeled binding partner conjugate and unreacted labeled binding partner along the strip by capillarity to the second region containing the immobilized analyte or analog thereof in which unreacted labeled binding partner is bound to the immobilized analyte in inverse relation-ship to the concentration of analyte in the fluid testsample.
The developed strip is read on an instrument having a detector capable of measuring the signal from the de-tectable label to determine the signal from the labeledbinding partner in the second region. The concentration of the analyte in the fluid test sample is determined by comparing the signal from the detectable label with de-terminations made in a similar manner using fluid test samples containing known concentrations of analyte.
MSE #1884 The sensitivity of the determination can be enhanced by providing a strip with a third region which region contains means for immobilizing the complex formed be-tween the analyte and the labeled binding partner there-for. For example, if the labeled binding partner in alabeled mouse antibody (IgG) is used, the complex of this mouse antibody and the analyte can be captured in a zone of immobilized goat anti-mouse IgG. By measuring the signal from the detectable label immobilized in this third region and determining the ratio of the signal la-beled binding partner in the second region to that in the third region, inaccuracies caused by uneven deposition of labeled conjugate and/or non-uniform fluid flow through the matrix can be corrected.
Detailed Description of the Invention The present invention is practiced by first provid-ing a test matrix through which the fluid test sample can flow by capillarity. Typically, the matrix will be in the form of a strip through which the test fluid flows horizontally although the matrix could be set up in lay-ers through which the test fluid could flow vertically from top to bottom or vice-versa. The following discus-sion will focus on the strip format.
The strip can be prepared from any matrix materialthrough which the test fluid and an analyte contained therein can flow by capillarity. The matrix can be of a material which is capable of non-bibulous lateral flow.
This type of flow is described in U.S. Patent 4,943,522 as liquid flow in which all of the dissolved or dispersed MSE #1884 2166~13 components of the liquid are carried through the matrix at substantially equal rates and with relatively unim-paired flow, as opposed to preferential retention of one or more components as would be the case if the matrix ma-terial were capable of adsorbing or imbibing one or moreof the components. An example of such a matrix material is the high density or ultra high molecular weight poly-ethylene sheet material from Porex Technologies of Fair-burn, GA. Equally suitable for use as the matrix mate-rial from which the chromatographic strips can be fabri-cated are bibulous materials such as paper, nitrocellu-lose and nylon.
Various immunochromatographic strip formats are suitable for use in conjunction with the present inven-tion. A particularly suitable format is that which is disclosed in U.S. Patent 4,446,232 wherein thele is de-scribed a device for the determination of the presence of antigens, which device comprises a strip of matrix mate-rial having a first zone in which there are provided im-mobilized analyte and enzyme linked antibodies specific to the analyte to be determined. The labeled antibodies can flow to a second zone when reacted with analyte in-troduced into the first zone but will not so flow in the absence of analyte in the test fluid due to being bound in the first zone by interaction with the immobilized analyte. The analyte is typically an antigen, although the format can be designed to detect the presence of an-tibodies as analyte. Modifications to this format are disclosed in U.S. Patent 4,868,108. In another modifica-tion, the enzyme substrate is disposed in the region of a second, immobilized antibody to thereby capture the com-MSE #1884 plex formed between the enzyme labeled antibody and theanalyte. This sort of format is particularly suitable for adaptation to the present invention, although any physically detectable signal may be used since the pres-ent invention need not be limited to the interaction ofan enzyme and its substrate to provide the detectable signal. Thus, by immobilizing the conjugate in a dis-crete detection zone located downstream on the strip from the zone in which the labeled binding partner for the analyte is bound, there are provided two zones from which the physically detectable property of the detectable la-bel can be measured to determine its concentration. By measuring the signal from the physically detectable prop-erty of the detectable label in the second zone contain-ing the immobilized analyte as the capture means and thesignal from the physically detectable property of the la-bel in the third zone, in which the immobilized antibody against the labeled binding partner is the capture means, and determining the ratio of these signals, the accuracy of the test for analyte concentration can be increased.
The accuracy is increased because this technique corrects for inaccuracies in labeled conjugate deposition and/or non-uniform fluid flow through the matrix. More particu-larly, since the aforementioned inaccuracies of labeled conjugate deposition and non-uniform fluid flow are usu-ally of small but significant magnitude, they do not dis-turb substantially the binding equilibrium. Therefore, the ratio of the signals in the two binding zones is a more accurate measure of the analyte concentration than is the signal in either zone by itself.
MSE #1884 2166~13 In a preferred embodiment of the present invention, there is provided a reflectance spectrometer with means for moving the strip or detector relative to each other such as a specimen table on which the strip is placed which can be moved laterally under the read head of the detector. In the case of the detectable physical prop-erty being reflectance of light at a predetermined wave-length, the detector is a spectrometer. This technique will assist in providing accurate quantitation for re-gions of the strip which may not have been precisely lo-cated with respect to the detection means of the spec-trometer. More specifically, the location of the strip relative to the detector can be under microprocessor con-trol, so that the reflectance of any desired region can be determined.
The method of practicing the present invention is more fully illustrated by the following examples:
Example I
Quantitation of HSA in a Sinqle ~locking Band Format An immunochromatographic strip containing a blocking band of immobilized HSA and a broad area of anti-HSA:gold sol conjugate in an Immunodyne~ nylon membrane was pre-pared. This strip is illustrated by Fig. 1 wherein the strip 10 contains blocking band 3, preceded by the anti-HSA:gold sol containing region 5 and the sample applica-tion area 7. These strips were prepared as follows:
MSE #1884 A 4.2 X 12.6 centimeter piece of Immunodyne~ mem-brane was placed on a Comag Thin Layer Chromatography (TLC) stripping apparatus with the long side parallel to the base and offset 1 cm up from the O position of the Y
axis. Next, a solution of human serum albumin (HSA) with a concentration of lO mg/mL was prepared in phosphate buffered saline (PBS; 0.137 M sodium chloride, 0.0027 M
potassium chloride, 0.010 M potassium phosphate, pH 7.4).
At a Y position of 3.5 cm a 6 cm long band of the 10 mg/mL HSA solution was stripped using the following set-tings of the TLC stripper:
(a) plate = 90, (b) band = 60, (c) sec/~L + 6, (d) volume = 6 ~L.
This gave a band 6 cm long and approximately 1 mm wide.
The stripping density was therefore 10 ~L/cm2 with a den-sity of 100 ~g of HSA/cm .
After 3 minutes the membrane was removed from the TLC stripper and placed in a flat plastic tray containing 0.5% casein (Hammerstein from Schlesinger) in phosphate buffered saline (pH 7.4 from Sigma) and gently rocked on an orbital shaker for 30 minutes.
At this point a wash buffer was prepared as 0.02%
sodium azide, 0.02% Tween 20 and 0.1% PEG 20 in PBS. The membrane was removed from the casein blocking solution and was twice washed with 25 mL of wash buffer for 30 minutes with gèntle rocking on an orbital buffer where-upon the membrane was removed from the wash buffer and allowed to dry overnight at room temperature.
MSE #1884 ` 2166913 Gold sol was prepared by adding 2.0 mL of a lO mg/mL
solution of acid gold chloride monohydrate (HC14Au H2O) to a refluxing 100C solution of tri-sodium citrate (0.00155 M). The refluxing was continued for 30 minutes and then cooled and filtered through a 0.2 ~M filter. Antibody-gold sol conjugate (Ab:gold sol) was prepared by adding 240 ~g of monoclonal antibody against human serum albumin and 50 ~L of 0.1 M potassium carbonate to 10 mL of the gold sol solution prepared as described above and the mixture was allowed to stir vigorously for 15 minutes, whereupon 0.5 mL of 1% (w/v) PEG-20 was added followed by another 10 minutes of vigorous stirring. At this point, 1.0 mL of 10% bovine serum albumin (BSA) in water was added and the mixture stirred vigorously for 10 minutes.
The Ab:gold sol was isolated by centrifugation at 14,500 X g for 30 minutes at 20C and then washed 10 times by suspending it in a wash buffer (1% BSA, 0.05% PEG-20, 2 mM sodium borate, pH = 9.0) and isolated by centrifuga-tion as described above. After the final centrifugation,the Ab:gold sol was suspended in l.0 mL of wash buffer and stored at 4C.
The dried membrane described above was again placed on the TLC stripper at an offset of 1 cm in the Y direc-tion as before. A mixture of 40 ~L of Ab:gold sol, 20 ~L
of 4% casein and 20 ~L of 1~ Methocel (K4M) + 0.6% poly-vinyl alcohol (PVA) was prepared and seven adjacent bands were stripped as before between the Y positions of 2.3 and 2.9 cm. The strip was allowed to dry at room tem-perature and slit into 0.5 cm wide strips before use.
MSE #1884 21669~3 A medium specific gravity (S.G.+1.017) pool of urine was filtered through an ultrafiltration membrane which held back proteins larger than 30,000 daltons. The fil-trate was used to prepare HSA solutions of various known concentrations by spiking them with an HSA solution of known concentration.
The strips were developed by suspending them verti-cally in a solution of HSA spiked urine filtrate to a depth of approximately 0.5 cm (on the end of the strip containing the Ab:gold sol conjugate bands) and allowing 5-10 minutes for the liquid to reach the top of the strip. These strips were allowed to air dry at room tem-perature and then mounted on plastic trycite handle mate-rial and analyzed.
The strips were developed with samples of an ul-trafiltrate of medium specific gravity urine containing 0, 1, 2, 3 and 5 mg/dL HSA. The strips from each sample concentration were read by measuring the reflectance at 557 nm on a CT100 reflectance photometer with scanning of the strip being simulated by cutting one millimeter off its end between measurements.
More particularly after the strips were developed with sample fluid and allowed to air dry at room tempera-ture, they were mounted on plastic handle material using double sided adhesive. The plastic/membrane laminate was trimmed to 7 mm (toward the sample application end) from the HSA band 3 (Fig. 1) which was visible due to the bound Ab:gold sol. The strip was then placed on the read table of a CT100 reflectance photometer with the strip MSE #1884 21 fig.913 pushed to the end stop. In this position the read area of the 10th pad position is 2.5 mm from the end of the strip. The reflectance of the 10th pad position was then measured after which 1 mm was cut from the end of the strip and the strip pushed to the end of the read table.
The lOt pad position was again read and this process was repeated until the end of the plastic and membrane lami-nate corresponded to a point which was 3 mm past the HSA
band. This technique was used to move the read head (detector) in relation to the read zone (HSA band) since software was not available to perform this task. With the proper software in place, the reflectance of the strip can be scanned by moving the read table with the plastic and membrane laminate past the readhead.
The results of this experiment are graphically il-lustrated by Fig. 2.
From Fig. 2 it can be determined that the depth of the troughs of the re1ectance scans of immunochroma-tographic strips developed with urine samples containing various concentrations of HSA are directly proportional to HSA concentration and a dose response to HSA can be seen in reflectance. Even though the gold sol band does not cover the entire read area, the reflectance is low-ered by between 10 and 15% when the band is in the read area. This 10 and 15% change in reflectance is detected even though much of the high reflectance (white) area is being measured along with the gold sol band.
If a mask with a narrow slit were added to the read-head area, the range of reflectance would be greatly in-MSE #1884 ~166~3 creased because the high reflectance white area would notbe in the read area at the same time as the gold sol band. This increased reflectance would allow better dis-crimination between analyte (HSA) concentrations. With the stepping motor, the spectrophotometer's strip table can be moved slowly through any area on the strip while taking consecutive readings to give good resolution for finding trough reflectances or areas in the troughs since the stepping motor can be moved a fraction of one revolu-tion at a time.
Example II
Quantitation of HSA in a Format Containinq a Blocking Band and a Capture Zone An immunochromatographic strip was prepared accord-ing to the methods of Example I and the format of Fig. 3.
Referring to Fig. 3, the strip 10 has a blocking band of immobilized HSA 3, a mouse anti-HSA:gold sol conjugate zone 5 and a capture band of immobilized goat anti-mouse IgG antibody 9. In preparing this band, a solution of goat anti-mouse IgG (sigma 8770) with a concentration of 5 mg/mL was prepared in 0.135 M sodium chloride. This was stripped as described above at a Y distance of 4.0 cm. The stripping density was 50 ~g of IgG/cm2. When the sample application zone 7 is immersed in a sample con-taining HSA to a depth less than that needed to immerse the conjugate zone 5, fluid will flow upward from the sample by capillary action. The HSA in the sample will complex with the gold sol:anti HSA in the conjugate zone and will move up the strip along with conjugate which is MSE #1884 21669~3 free since it did not find any HSA to bind as there was a molar excess of conjugate to HSA in the sample. The free conjugate will bind the immobilized HSA in the blocking band 3 while the gold sol-anti HSA:HSA complex will con-tinue to flow up the strip where it will be bound by theimmobilized goat anti mouse IgG antibody in the capture band 9.
Strips of this format were developed with samples of medium SG urine ultrafiltrate containing concentrations of HSA of 0, 0.5, 0.8, 1.0, 1.5 and 2.0 mg/dL. Duplicate strips for each HSA concentration were run. Reflectance data at 557 nm was collected on the CT100 using a method for visually aligning the bands in the center of the 10th pad position. The 10th pad position occupies the 5 mm portion adjacent to the end of the Multistix~ 10 SG urine strip product. The Multistix 10 SG product -.s an ap-proximately 10.9 cm long by 5 mm wide by 0.5 mm thick piece of plastic to which 10 paper pads containing dried reagents each 5 mm by 5 mm are attached. The 10th pad is aligned evenly with one end of the plastic and the spac-ing between the pads is 2.5 mm leaving a 3.4 cm piece of the plastic at the other end which has no pads and serves as a handle area. In Fig. 4a there are plotted the re-sults of this experiment in terms of reflectance. Inthis figure, in which the reflectance is from the immobi-lized HSA band 3 (Fig. 3), the dose response to HSA is linear in terms of reflectance (R) with two outlying val-ues. The response of the goat anti-mouse IgG band 9 (Fig. 3) to HSA, as represented in Fig. 4b, is more scat-tered and most of the reflectance drop occurred between 0 and 0.5 mg/dL HSA. However, when the reflectance value MSE #1884 ` 2l6fi9l~
for the HSA band is ratioed to the reflectance (R) value for the goat anti-mouse IgG band the variability de-creases as can be determined from Fig. 4c which plots the concentration of HSA against the ratio of reflectance of the HSA band to the reflectance of the goat anti-mouse IgG band. A curved but smooth dose response to HSA con-centration is observed in Fig. 4c. This ratio can be re-versed which would amount to taking the reciprocal of each ratio which would have the same effect as the ratio itself. Thus, the determination of the ratio of these two reflectance values corrects for the variability of the conjugate deposition during reagent preparation, and any unevenness in the fluid flow during the development of the strip with sample, i.e. if there is less gold sol:anti HSA on one strip than on another, the ratio of the two bands will provide a result which is corrected for the unevenness in preparation. Unevenness in fluid flow during development of the strip can be corrected for in a similar manner.
Example III
Quantitation of HSA and IqG in a Dual Blockinq Band For-mat Immunochromatography strips were constructed to measure both human serum albumin (HSA) and human (H) IgG
in order to quantify each of these analytes independ-ently. The strips were prepared from ImmunodyneTM nylon according to the scheme of Fig. 5 to comprise a sample application zone 1 followed by a zone 3 containing gold sol labeled anti-HSA and gold sol labeled anti-(H)IgG
MSE #1884 216~9~3 conjugates. The strip contained two blocking bands; the first blocking band 5, containing immobilized HSA, and the second blocking band 7, containing immobilized (H)IgG.
These strips were developed with test samples of an ultrafiltrate of medium SG urine containing 0, 5, 10, 15, 20, 30 and 40 mg/L HSA along with either 0 IgG or 100 mg/L (H)IgG. Two strips for each HSA concentration were examined by measuring the reflectance at 557 nm on a CT100 reflectance photometer by physically cutting and aligning the strip in the 10th pad position of the Multis-tix~ SG strip to obtain reflectance readings. Fig. 6 graphically represents the reflectance for samples con-taining both HSA and (H)IgG blocking bands using testsamples which did not contain IgG. Fig. 7 shows similar data for test samples containing 100 mg/L (H)IgG along with the various concentrations of HSA. From the data of Fig. 6 it can be determined that the reflectance of the HSA blocking band is directly proportional to the HSA
concentration in the sample and the reflectance of the (H)IgG blocking band is approximately 0.88 (based on a maximum total reflectance of 1.0) due to the gold sol:anti (H)IgG which binds to it in the absence of (H)IgG in the sample. The data in Fig. 7 show the same direct proportionality of the reflectance to HSA concen-tration as do the data in Fig. 6, but the reflectance of the (H)IgG band is higher (`0.91-0.92) due to the 100 mg/L
(H)IgG in the sample. The (H)IgG binds to the gold sol-anti(H)IgG conjugate and will not allow it to bind to theimmobilized (H)IgG in the (H)IgG blocking band. This demonstrates that the dose response to HSA is the same in MSE #1884 21~9~3 the presence or absence of (H)IgG and that there is a separate dose response to (H)IgG. Accordingly, by using a strip with mixed gold sol antibody conjugates against two different analytes and in separate regions having im-mobilized bands of these analytes or analogs thereof, onecan obtain a separate instrumentally detectable dose re-sponse to each analyte. This is important because it en-ables one to quantitate more than one analyte using a single immunochromatographic strip.
MSE #1884
QUANTITATIVE DETECTION OF ANALYTES
ON IMMUNOCHROMATOGRAPHIC STRIPS
Background of the Invention Immunochromatographic strip formats are increasingly popular for qualitative and semi-quantitative assays which use visual detection schemes. This type of immuno-assay involves the application of a liquid test samplesuspected of containing an analyte to be detected to an application zone of an immunochromatographic test strip.
The strip is comprised of a matrix material through which the test fluid and analyte suspended or dissolved therein can flow by capillarity from the application zone to a detection zone where a visible signal, or absence of such, reveals the presence of the analyte. Typically, the strip will include means for immunospecifically bind-ing the analyte to be detected with its specific binding partner which bears a detectable label. In one such scheme; as disclosed in U.S. Patent 4,446,232; the strip contains an enzyme labeled, mobile binding partner for the analyte which is in a zone downstream from the sample application zone. If analyte is present in the test sam-ple, it will combine with its labeled binding partner toform a complex which will flow along the strip to a de-tection zone which contains a substrate for the enzyme label capable of providing a colored response in the presence of the enzyme label. The strip contains a zone in which analyte is immobilized, so that labeled binding partner which does not combine with analyte, due to ab-sence of analyte in the sample, will be captured and thereby inhibited from reaching the detection zone.
There have been published various modifications of this MSE #1884 technique, all of which involve some competitive specific binding system in which the presence or absence of ana-lyte in the test sample is determined by the detection or lack thereof of labeled binding partner in the detection zone. In U.S. Patent 4,868,108 there is disclosed a similar scheme with the addition of an immobilized cap-ture reagent for the enzyme labeled binding partner in the detection zone to concentrate the enzyme label and enhance its ability to react with the enzyme substrate and thereby render the assay more sensitive.
Not all of the schemes for immunochromatography rely on an enzyme labeled binding partner/enzyme substrate as providing the signal for detection of the analyte. In U.S. Patent 4,806,311 there is disclosed a multizone test device for the specific binding assay determination of an analyte and an immobilized binding partner the-efore to-gether with a detection zone for receiving labeled rea-gent which migrates thereto from the reagent zone. The detection zone contains an immobilized form of a binding substance for the labeled reagent. The labeled reagent bears a detectable chemical group having a detectable physical property which is detectable on the basis of its own physical properties, so that it does not require a chemical reaction with another substance. Exemplary of such groups are colored species fluorescers, phosphores-cent molecules, radioisotopes and electroactive moieties.
United States Patent 4,313,734 describes the use of gold sols as labels for antibodies which are detectable without a chemical change.
MSE #1884 Immunochromatographic strip formats provide a viable system for the determination of various analytes (whether they be antigens or antibodies) but suffer from the limi-tation that they yield results which are at best semi-quantitative when, for some analytes, a quantitative an-swer is required. Accordingly, it would be desirable and it is an object of the present invention to provide a means for quantifying the results of analyses carried out by the use of immunochromatographic strip formats.
Summary of the Invention The present invention involves an improvement to a method for determining an analyte in a test fluid which involves applying the test fluid to an immunochroma-tographic matrix which allows the test fluid; and the analyte, if present; to flow through the matrix by capil-larity and which matrix contains a labeled binding part-ner for the analyte. The matrix, which is normally in the form of a test strip, also contains at least one de-tection zone in which the presence or absence of the ana-lyte is determined by detecting the label carried by the specific binding partner. The improvement involves de-termining the concentration of the label using an instru-ment having a detector capable of determining its concen-tration in the detection zone(s).
In a preferred embodiment of the present invention there is provided a test strip comprising a strip having a first region which contains mobile specific binding partner for the analyte which bears a detectable label and can react with the analyte to form an analyte/labeled MSE #1884 binding partner complex and at least one second region which contains an immobilized analyte or analog thereof.
The term analog as used herein refers to any substance capable of being bound by the active site of the specific binding partner.
The strip as described above is developed by apply-ing the test fluid sample suspected of containing the analyte thereto thereby allowing it to contact the mo-bile, labeled specific binding partner for the analytewhereby analyte present in the fluid test sample binds to the labeled specific binding partner to form the complex;
leaving excess, unreacted labeled binding partner free to further react whereby the fluid test sample carries the analyte~labeled binding partner conjugate and unreacted labeled binding partner along the strip by capillarity to the second region containing the immobilized analyte or analog thereof in which unreacted labeled binding partner is bound to the immobilized analyte in inverse relation-ship to the concentration of analyte in the fluid testsample.
The developed strip is read on an instrument having a detector capable of measuring the signal from the de-tectable label to determine the signal from the labeledbinding partner in the second region. The concentration of the analyte in the fluid test sample is determined by comparing the signal from the detectable label with de-terminations made in a similar manner using fluid test samples containing known concentrations of analyte.
MSE #1884 The sensitivity of the determination can be enhanced by providing a strip with a third region which region contains means for immobilizing the complex formed be-tween the analyte and the labeled binding partner there-for. For example, if the labeled binding partner in alabeled mouse antibody (IgG) is used, the complex of this mouse antibody and the analyte can be captured in a zone of immobilized goat anti-mouse IgG. By measuring the signal from the detectable label immobilized in this third region and determining the ratio of the signal la-beled binding partner in the second region to that in the third region, inaccuracies caused by uneven deposition of labeled conjugate and/or non-uniform fluid flow through the matrix can be corrected.
Detailed Description of the Invention The present invention is practiced by first provid-ing a test matrix through which the fluid test sample can flow by capillarity. Typically, the matrix will be in the form of a strip through which the test fluid flows horizontally although the matrix could be set up in lay-ers through which the test fluid could flow vertically from top to bottom or vice-versa. The following discus-sion will focus on the strip format.
The strip can be prepared from any matrix materialthrough which the test fluid and an analyte contained therein can flow by capillarity. The matrix can be of a material which is capable of non-bibulous lateral flow.
This type of flow is described in U.S. Patent 4,943,522 as liquid flow in which all of the dissolved or dispersed MSE #1884 2166~13 components of the liquid are carried through the matrix at substantially equal rates and with relatively unim-paired flow, as opposed to preferential retention of one or more components as would be the case if the matrix ma-terial were capable of adsorbing or imbibing one or moreof the components. An example of such a matrix material is the high density or ultra high molecular weight poly-ethylene sheet material from Porex Technologies of Fair-burn, GA. Equally suitable for use as the matrix mate-rial from which the chromatographic strips can be fabri-cated are bibulous materials such as paper, nitrocellu-lose and nylon.
Various immunochromatographic strip formats are suitable for use in conjunction with the present inven-tion. A particularly suitable format is that which is disclosed in U.S. Patent 4,446,232 wherein thele is de-scribed a device for the determination of the presence of antigens, which device comprises a strip of matrix mate-rial having a first zone in which there are provided im-mobilized analyte and enzyme linked antibodies specific to the analyte to be determined. The labeled antibodies can flow to a second zone when reacted with analyte in-troduced into the first zone but will not so flow in the absence of analyte in the test fluid due to being bound in the first zone by interaction with the immobilized analyte. The analyte is typically an antigen, although the format can be designed to detect the presence of an-tibodies as analyte. Modifications to this format are disclosed in U.S. Patent 4,868,108. In another modifica-tion, the enzyme substrate is disposed in the region of a second, immobilized antibody to thereby capture the com-MSE #1884 plex formed between the enzyme labeled antibody and theanalyte. This sort of format is particularly suitable for adaptation to the present invention, although any physically detectable signal may be used since the pres-ent invention need not be limited to the interaction ofan enzyme and its substrate to provide the detectable signal. Thus, by immobilizing the conjugate in a dis-crete detection zone located downstream on the strip from the zone in which the labeled binding partner for the analyte is bound, there are provided two zones from which the physically detectable property of the detectable la-bel can be measured to determine its concentration. By measuring the signal from the physically detectable prop-erty of the detectable label in the second zone contain-ing the immobilized analyte as the capture means and thesignal from the physically detectable property of the la-bel in the third zone, in which the immobilized antibody against the labeled binding partner is the capture means, and determining the ratio of these signals, the accuracy of the test for analyte concentration can be increased.
The accuracy is increased because this technique corrects for inaccuracies in labeled conjugate deposition and/or non-uniform fluid flow through the matrix. More particu-larly, since the aforementioned inaccuracies of labeled conjugate deposition and non-uniform fluid flow are usu-ally of small but significant magnitude, they do not dis-turb substantially the binding equilibrium. Therefore, the ratio of the signals in the two binding zones is a more accurate measure of the analyte concentration than is the signal in either zone by itself.
MSE #1884 2166~13 In a preferred embodiment of the present invention, there is provided a reflectance spectrometer with means for moving the strip or detector relative to each other such as a specimen table on which the strip is placed which can be moved laterally under the read head of the detector. In the case of the detectable physical prop-erty being reflectance of light at a predetermined wave-length, the detector is a spectrometer. This technique will assist in providing accurate quantitation for re-gions of the strip which may not have been precisely lo-cated with respect to the detection means of the spec-trometer. More specifically, the location of the strip relative to the detector can be under microprocessor con-trol, so that the reflectance of any desired region can be determined.
The method of practicing the present invention is more fully illustrated by the following examples:
Example I
Quantitation of HSA in a Sinqle ~locking Band Format An immunochromatographic strip containing a blocking band of immobilized HSA and a broad area of anti-HSA:gold sol conjugate in an Immunodyne~ nylon membrane was pre-pared. This strip is illustrated by Fig. 1 wherein the strip 10 contains blocking band 3, preceded by the anti-HSA:gold sol containing region 5 and the sample applica-tion area 7. These strips were prepared as follows:
MSE #1884 A 4.2 X 12.6 centimeter piece of Immunodyne~ mem-brane was placed on a Comag Thin Layer Chromatography (TLC) stripping apparatus with the long side parallel to the base and offset 1 cm up from the O position of the Y
axis. Next, a solution of human serum albumin (HSA) with a concentration of lO mg/mL was prepared in phosphate buffered saline (PBS; 0.137 M sodium chloride, 0.0027 M
potassium chloride, 0.010 M potassium phosphate, pH 7.4).
At a Y position of 3.5 cm a 6 cm long band of the 10 mg/mL HSA solution was stripped using the following set-tings of the TLC stripper:
(a) plate = 90, (b) band = 60, (c) sec/~L + 6, (d) volume = 6 ~L.
This gave a band 6 cm long and approximately 1 mm wide.
The stripping density was therefore 10 ~L/cm2 with a den-sity of 100 ~g of HSA/cm .
After 3 minutes the membrane was removed from the TLC stripper and placed in a flat plastic tray containing 0.5% casein (Hammerstein from Schlesinger) in phosphate buffered saline (pH 7.4 from Sigma) and gently rocked on an orbital shaker for 30 minutes.
At this point a wash buffer was prepared as 0.02%
sodium azide, 0.02% Tween 20 and 0.1% PEG 20 in PBS. The membrane was removed from the casein blocking solution and was twice washed with 25 mL of wash buffer for 30 minutes with gèntle rocking on an orbital buffer where-upon the membrane was removed from the wash buffer and allowed to dry overnight at room temperature.
MSE #1884 ` 2166913 Gold sol was prepared by adding 2.0 mL of a lO mg/mL
solution of acid gold chloride monohydrate (HC14Au H2O) to a refluxing 100C solution of tri-sodium citrate (0.00155 M). The refluxing was continued for 30 minutes and then cooled and filtered through a 0.2 ~M filter. Antibody-gold sol conjugate (Ab:gold sol) was prepared by adding 240 ~g of monoclonal antibody against human serum albumin and 50 ~L of 0.1 M potassium carbonate to 10 mL of the gold sol solution prepared as described above and the mixture was allowed to stir vigorously for 15 minutes, whereupon 0.5 mL of 1% (w/v) PEG-20 was added followed by another 10 minutes of vigorous stirring. At this point, 1.0 mL of 10% bovine serum albumin (BSA) in water was added and the mixture stirred vigorously for 10 minutes.
The Ab:gold sol was isolated by centrifugation at 14,500 X g for 30 minutes at 20C and then washed 10 times by suspending it in a wash buffer (1% BSA, 0.05% PEG-20, 2 mM sodium borate, pH = 9.0) and isolated by centrifuga-tion as described above. After the final centrifugation,the Ab:gold sol was suspended in l.0 mL of wash buffer and stored at 4C.
The dried membrane described above was again placed on the TLC stripper at an offset of 1 cm in the Y direc-tion as before. A mixture of 40 ~L of Ab:gold sol, 20 ~L
of 4% casein and 20 ~L of 1~ Methocel (K4M) + 0.6% poly-vinyl alcohol (PVA) was prepared and seven adjacent bands were stripped as before between the Y positions of 2.3 and 2.9 cm. The strip was allowed to dry at room tem-perature and slit into 0.5 cm wide strips before use.
MSE #1884 21669~3 A medium specific gravity (S.G.+1.017) pool of urine was filtered through an ultrafiltration membrane which held back proteins larger than 30,000 daltons. The fil-trate was used to prepare HSA solutions of various known concentrations by spiking them with an HSA solution of known concentration.
The strips were developed by suspending them verti-cally in a solution of HSA spiked urine filtrate to a depth of approximately 0.5 cm (on the end of the strip containing the Ab:gold sol conjugate bands) and allowing 5-10 minutes for the liquid to reach the top of the strip. These strips were allowed to air dry at room tem-perature and then mounted on plastic trycite handle mate-rial and analyzed.
The strips were developed with samples of an ul-trafiltrate of medium specific gravity urine containing 0, 1, 2, 3 and 5 mg/dL HSA. The strips from each sample concentration were read by measuring the reflectance at 557 nm on a CT100 reflectance photometer with scanning of the strip being simulated by cutting one millimeter off its end between measurements.
More particularly after the strips were developed with sample fluid and allowed to air dry at room tempera-ture, they were mounted on plastic handle material using double sided adhesive. The plastic/membrane laminate was trimmed to 7 mm (toward the sample application end) from the HSA band 3 (Fig. 1) which was visible due to the bound Ab:gold sol. The strip was then placed on the read table of a CT100 reflectance photometer with the strip MSE #1884 21 fig.913 pushed to the end stop. In this position the read area of the 10th pad position is 2.5 mm from the end of the strip. The reflectance of the 10th pad position was then measured after which 1 mm was cut from the end of the strip and the strip pushed to the end of the read table.
The lOt pad position was again read and this process was repeated until the end of the plastic and membrane lami-nate corresponded to a point which was 3 mm past the HSA
band. This technique was used to move the read head (detector) in relation to the read zone (HSA band) since software was not available to perform this task. With the proper software in place, the reflectance of the strip can be scanned by moving the read table with the plastic and membrane laminate past the readhead.
The results of this experiment are graphically il-lustrated by Fig. 2.
From Fig. 2 it can be determined that the depth of the troughs of the re1ectance scans of immunochroma-tographic strips developed with urine samples containing various concentrations of HSA are directly proportional to HSA concentration and a dose response to HSA can be seen in reflectance. Even though the gold sol band does not cover the entire read area, the reflectance is low-ered by between 10 and 15% when the band is in the read area. This 10 and 15% change in reflectance is detected even though much of the high reflectance (white) area is being measured along with the gold sol band.
If a mask with a narrow slit were added to the read-head area, the range of reflectance would be greatly in-MSE #1884 ~166~3 creased because the high reflectance white area would notbe in the read area at the same time as the gold sol band. This increased reflectance would allow better dis-crimination between analyte (HSA) concentrations. With the stepping motor, the spectrophotometer's strip table can be moved slowly through any area on the strip while taking consecutive readings to give good resolution for finding trough reflectances or areas in the troughs since the stepping motor can be moved a fraction of one revolu-tion at a time.
Example II
Quantitation of HSA in a Format Containinq a Blocking Band and a Capture Zone An immunochromatographic strip was prepared accord-ing to the methods of Example I and the format of Fig. 3.
Referring to Fig. 3, the strip 10 has a blocking band of immobilized HSA 3, a mouse anti-HSA:gold sol conjugate zone 5 and a capture band of immobilized goat anti-mouse IgG antibody 9. In preparing this band, a solution of goat anti-mouse IgG (sigma 8770) with a concentration of 5 mg/mL was prepared in 0.135 M sodium chloride. This was stripped as described above at a Y distance of 4.0 cm. The stripping density was 50 ~g of IgG/cm2. When the sample application zone 7 is immersed in a sample con-taining HSA to a depth less than that needed to immerse the conjugate zone 5, fluid will flow upward from the sample by capillary action. The HSA in the sample will complex with the gold sol:anti HSA in the conjugate zone and will move up the strip along with conjugate which is MSE #1884 21669~3 free since it did not find any HSA to bind as there was a molar excess of conjugate to HSA in the sample. The free conjugate will bind the immobilized HSA in the blocking band 3 while the gold sol-anti HSA:HSA complex will con-tinue to flow up the strip where it will be bound by theimmobilized goat anti mouse IgG antibody in the capture band 9.
Strips of this format were developed with samples of medium SG urine ultrafiltrate containing concentrations of HSA of 0, 0.5, 0.8, 1.0, 1.5 and 2.0 mg/dL. Duplicate strips for each HSA concentration were run. Reflectance data at 557 nm was collected on the CT100 using a method for visually aligning the bands in the center of the 10th pad position. The 10th pad position occupies the 5 mm portion adjacent to the end of the Multistix~ 10 SG urine strip product. The Multistix 10 SG product -.s an ap-proximately 10.9 cm long by 5 mm wide by 0.5 mm thick piece of plastic to which 10 paper pads containing dried reagents each 5 mm by 5 mm are attached. The 10th pad is aligned evenly with one end of the plastic and the spac-ing between the pads is 2.5 mm leaving a 3.4 cm piece of the plastic at the other end which has no pads and serves as a handle area. In Fig. 4a there are plotted the re-sults of this experiment in terms of reflectance. Inthis figure, in which the reflectance is from the immobi-lized HSA band 3 (Fig. 3), the dose response to HSA is linear in terms of reflectance (R) with two outlying val-ues. The response of the goat anti-mouse IgG band 9 (Fig. 3) to HSA, as represented in Fig. 4b, is more scat-tered and most of the reflectance drop occurred between 0 and 0.5 mg/dL HSA. However, when the reflectance value MSE #1884 ` 2l6fi9l~
for the HSA band is ratioed to the reflectance (R) value for the goat anti-mouse IgG band the variability de-creases as can be determined from Fig. 4c which plots the concentration of HSA against the ratio of reflectance of the HSA band to the reflectance of the goat anti-mouse IgG band. A curved but smooth dose response to HSA con-centration is observed in Fig. 4c. This ratio can be re-versed which would amount to taking the reciprocal of each ratio which would have the same effect as the ratio itself. Thus, the determination of the ratio of these two reflectance values corrects for the variability of the conjugate deposition during reagent preparation, and any unevenness in the fluid flow during the development of the strip with sample, i.e. if there is less gold sol:anti HSA on one strip than on another, the ratio of the two bands will provide a result which is corrected for the unevenness in preparation. Unevenness in fluid flow during development of the strip can be corrected for in a similar manner.
Example III
Quantitation of HSA and IqG in a Dual Blockinq Band For-mat Immunochromatography strips were constructed to measure both human serum albumin (HSA) and human (H) IgG
in order to quantify each of these analytes independ-ently. The strips were prepared from ImmunodyneTM nylon according to the scheme of Fig. 5 to comprise a sample application zone 1 followed by a zone 3 containing gold sol labeled anti-HSA and gold sol labeled anti-(H)IgG
MSE #1884 216~9~3 conjugates. The strip contained two blocking bands; the first blocking band 5, containing immobilized HSA, and the second blocking band 7, containing immobilized (H)IgG.
These strips were developed with test samples of an ultrafiltrate of medium SG urine containing 0, 5, 10, 15, 20, 30 and 40 mg/L HSA along with either 0 IgG or 100 mg/L (H)IgG. Two strips for each HSA concentration were examined by measuring the reflectance at 557 nm on a CT100 reflectance photometer by physically cutting and aligning the strip in the 10th pad position of the Multis-tix~ SG strip to obtain reflectance readings. Fig. 6 graphically represents the reflectance for samples con-taining both HSA and (H)IgG blocking bands using testsamples which did not contain IgG. Fig. 7 shows similar data for test samples containing 100 mg/L (H)IgG along with the various concentrations of HSA. From the data of Fig. 6 it can be determined that the reflectance of the HSA blocking band is directly proportional to the HSA
concentration in the sample and the reflectance of the (H)IgG blocking band is approximately 0.88 (based on a maximum total reflectance of 1.0) due to the gold sol:anti (H)IgG which binds to it in the absence of (H)IgG in the sample. The data in Fig. 7 show the same direct proportionality of the reflectance to HSA concen-tration as do the data in Fig. 6, but the reflectance of the (H)IgG band is higher (`0.91-0.92) due to the 100 mg/L
(H)IgG in the sample. The (H)IgG binds to the gold sol-anti(H)IgG conjugate and will not allow it to bind to theimmobilized (H)IgG in the (H)IgG blocking band. This demonstrates that the dose response to HSA is the same in MSE #1884 21~9~3 the presence or absence of (H)IgG and that there is a separate dose response to (H)IgG. Accordingly, by using a strip with mixed gold sol antibody conjugates against two different analytes and in separate regions having im-mobilized bands of these analytes or analogs thereof, onecan obtain a separate instrumentally detectable dose re-sponse to each analyte. This is important because it en-ables one to quantitate more than one analyte using a single immunochromatographic strip.
MSE #1884
Claims (17)
1. In a method for determining an analyte in a fluid test sample which involves applying the fluid to an immu-nochromatographic matrix whereby the fluid test sample flows up along the matrix by capillarity and which matrix contains a labeled binding partner for the analyte and has at least one detection zone in which the analyte is determined by detecting the label contained by the la-beled binding partner, the improvement which comprises determining the signal from the label using an instrument having a detector capable of determining its signal in the detection zone.
2. A method for determining the concentration of one or more analyte in a fluid test sample which comprises:
a) providing a test strip comprising a matrix through which the fluid test sample can flow by cap-illarity wherein a first region of the strip con-tains mobile specific binding partner for the ana-lyte which bears a detectable label and can react with the analyte to form an analyte/labeled binding partner complex and at least one second region which contains an immobilized analyte or analog thereof, b) developing the strip by applying the fluid test sample suspected of containing the analyte thereto thereby allowing it to contact the mobile, labeled specific binding partner for the analyte whereby analyte present in the fluid test sample binds to the labeled specific binding partner to form the complex leaving excess, unreacted labeled binding partner free to further react whereby the fluid test sample carries the analyte/labeled binding partner complex and unreacted labeled binding partner along the strip by capillarity to the second region con-taining the immobilized analyte or analog thereof in which region unreacted labeled binding partner is bound to the immobilized analyte in inverse rela-tionship to the concentration of analyte in the fluid test sample, c) reading the developed strip on an instrument having a detector capable of measuring the signal from the detectable label to determine the concern-tration of the labeled binding partner in the second region, and d) determining the concentration of analyte in the fluid test sample by comparing the signal from the detectable label measured in step c) with the meas-urements of the signal made in a similar manner us-ing fluid samples containing known concentrations of analyte.
a) providing a test strip comprising a matrix through which the fluid test sample can flow by cap-illarity wherein a first region of the strip con-tains mobile specific binding partner for the ana-lyte which bears a detectable label and can react with the analyte to form an analyte/labeled binding partner complex and at least one second region which contains an immobilized analyte or analog thereof, b) developing the strip by applying the fluid test sample suspected of containing the analyte thereto thereby allowing it to contact the mobile, labeled specific binding partner for the analyte whereby analyte present in the fluid test sample binds to the labeled specific binding partner to form the complex leaving excess, unreacted labeled binding partner free to further react whereby the fluid test sample carries the analyte/labeled binding partner complex and unreacted labeled binding partner along the strip by capillarity to the second region con-taining the immobilized analyte or analog thereof in which region unreacted labeled binding partner is bound to the immobilized analyte in inverse rela-tionship to the concentration of analyte in the fluid test sample, c) reading the developed strip on an instrument having a detector capable of measuring the signal from the detectable label to determine the concern-tration of the labeled binding partner in the second region, and d) determining the concentration of analyte in the fluid test sample by comparing the signal from the detectable label measured in step c) with the meas-urements of the signal made in a similar manner us-ing fluid samples containing known concentrations of analyte.
3. The method of Claim 2 wherein there is a third re-gion of the strip which contains means for immobilizing the complex formed between the analyte and the labeled binding partner and measuring the signal from the detect-able label immobilized in this third region and wherein the ratio of the signal from the labeled binding partner immobilized in the second region and the immobilized com-plex in the third region is determined.
4. The method of Claim 2 wherein the instrument con-tains means for moving the strip or the detector relative to each other to give accurate quantitation for regions which may not have been precisely located on the instru-ment.
5. The method of Claim 2 wherein there are two or more mobile labeled binding partners on the strip in the same or different regions and two or more regions containing immobilized analytes or analogs thereof, so that two or more analytes can be determined in a single test.
6. The method of Claim 2 wherein the instrument is a reflectance spectrometer.
7. The method of Claim 2 wherein the matrix is com-prised of a material which is capable of non-bibulous lateral flow or a bibulous material.
8. The method of Claim 2 wherein the analyte is human serum albumin (HSA).
9. The method of Claim 2 wherein the detectable label is a colored species.
10. The method of Claim 9 wherein the colored species is a gold sol.
11. The method of Claim 2 wherein the labeled binding partner is an antibody.
12. A method for quantitatively determining the concen-tration of one or more analyte in a fluid test sample which comprises the steps of:
a) providing a test strip comprising a matrix through which the fluid test sample can flow by cap-illarity said strip having a first region wherein the first region contains mobile specific binding partner for the analyte which binding partner bears a detectable label and can react with the analyte to form an analyte/labeled binding partner complex, at least one second region which contains an immobi-lized analyte or analog thereof and at least one third region which contains means for immobilizing the complex formed between the analyte and labeled binding partner;
b) developing the strip by applying the fluid test sample suspected of containing the analyte thereto to allow it to contact the mobile specific binding partner whereby analyte present in the fluid test sample binds to the labeled specific binding partner to form the complex leaving excess, unreacted la-beled binding partner free to further react whereby the fluid test sample carries the analyte/labeled binding partner complex and unreacted labeled bind-ing partner along the strip by capillarity to the second region containing the immobilized analyte or analog thereof in which region unreacted labeled binding partner is bound to the immobilized analyte in inverse relationship to the concentration of the analyte in the fluid test sample and the ana-lyte/labeled binding partner complex is carried by capillarity to the third region where it is captured by the immobilization means;
c) reading the second zone of the developed strip on an instrument having a detector capable of meas-uring the signal from the detectable label to deter-mine the concentration of the labeled binding part-ner in the second zone and reading the third zone of the developed strip in a similar manner to determine the signal from the labeled binding partner in the third zone of the strip;
d) determining the ratio of the signal from the labeled binding partner immobilized in the second region to the signal from the labeled binding part-ner in the third region; and e) determining the concentration of the analyte in the fluid test sample by comparing the ratio of the signals measured in step c with the measurements of the ratios of the signals measured in a similar man-ner for fluid samples containing known concentra-tions of the analyte.
a) providing a test strip comprising a matrix through which the fluid test sample can flow by cap-illarity said strip having a first region wherein the first region contains mobile specific binding partner for the analyte which binding partner bears a detectable label and can react with the analyte to form an analyte/labeled binding partner complex, at least one second region which contains an immobi-lized analyte or analog thereof and at least one third region which contains means for immobilizing the complex formed between the analyte and labeled binding partner;
b) developing the strip by applying the fluid test sample suspected of containing the analyte thereto to allow it to contact the mobile specific binding partner whereby analyte present in the fluid test sample binds to the labeled specific binding partner to form the complex leaving excess, unreacted la-beled binding partner free to further react whereby the fluid test sample carries the analyte/labeled binding partner complex and unreacted labeled bind-ing partner along the strip by capillarity to the second region containing the immobilized analyte or analog thereof in which region unreacted labeled binding partner is bound to the immobilized analyte in inverse relationship to the concentration of the analyte in the fluid test sample and the ana-lyte/labeled binding partner complex is carried by capillarity to the third region where it is captured by the immobilization means;
c) reading the second zone of the developed strip on an instrument having a detector capable of meas-uring the signal from the detectable label to deter-mine the concentration of the labeled binding part-ner in the second zone and reading the third zone of the developed strip in a similar manner to determine the signal from the labeled binding partner in the third zone of the strip;
d) determining the ratio of the signal from the labeled binding partner immobilized in the second region to the signal from the labeled binding part-ner in the third region; and e) determining the concentration of the analyte in the fluid test sample by comparing the ratio of the signals measured in step c with the measurements of the ratios of the signals measured in a similar man-ner for fluid samples containing known concentra-tions of the analyte.
13. The method of Claim 12 wherein the measuring instru-ment is a reflectance spectrometer.
14. The method of Claim 12 wherein the matrix is com-prised of a material which is capable of non-bibulous lateral flow or a bibulous material.
15. The method of Claim 12 wherein the analyte is human serum albumin (HSA).
16. The method of Claim 12 wherein the detectable label is a gold sol.
17. The method of Claim 12 wherein the labeled binding partner is an antibody.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/380,119 US5569608A (en) | 1995-01-30 | 1995-01-30 | Quantitative detection of analytes on immunochromatographic strips |
US08/380,119 | 1995-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2166913A1 true CA2166913A1 (en) | 1996-07-31 |
Family
ID=23499982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002166913A Abandoned CA2166913A1 (en) | 1995-01-30 | 1996-01-10 | Quantitative detection of analytes on immunochromatographic strips |
Country Status (8)
Country | Link |
---|---|
US (1) | US5569608A (en) |
EP (1) | EP0724157A2 (en) |
JP (1) | JPH08240591A (en) |
KR (1) | KR960029790A (en) |
CN (1) | CN1146557A (en) |
AU (1) | AU4222696A (en) |
CA (1) | CA2166913A1 (en) |
ZA (1) | ZA96357B (en) |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69219686T2 (en) * | 1991-07-29 | 1997-09-11 | Mochida Pharm Co Ltd | Method and device for use in specific binding tests |
US7635597B2 (en) * | 1995-08-09 | 2009-12-22 | Bayer Healthcare Llc | Dry reagent particle assay and device having multiple test zones and method therefor |
US5945345A (en) * | 1996-08-27 | 1999-08-31 | Metrika, Inc. | Device for preventing assay interference using silver or lead to remove the interferant |
US6001658A (en) * | 1996-09-13 | 1999-12-14 | Diagnostic Chemicals Limited | Test strip apparatus and method for determining presence of analyte in a fluid sample |
US6194221B1 (en) * | 1996-11-19 | 2001-02-27 | Wyntek Diagnostics, Inc. | Hybrid one-step immunochromatographic device and method of use |
US5879951A (en) | 1997-01-29 | 1999-03-09 | Smithkline Diagnostics, Inc. | Opposable-element assay device employing unidirectional flow |
US5939252A (en) | 1997-05-09 | 1999-08-17 | Lennon; Donald J. | Detachable-element assay device |
EP1701164B1 (en) * | 1997-07-16 | 2009-03-11 | Charm Sciences Inc. | Method for detecting the presence of a residue analyte in a sample |
US6436721B1 (en) * | 1997-07-25 | 2002-08-20 | Bayer Corporation | Device and method for obtaining clinically significant analyte ratios |
US6437563B1 (en) * | 1997-11-21 | 2002-08-20 | Quantum Design, Inc. | Method and apparatus for making measurements of accumulations of magnetically susceptible particles combined with analytes |
US8071384B2 (en) | 1997-12-22 | 2011-12-06 | Roche Diagnostics Operations, Inc. | Control and calibration solutions and methods for their use |
US7713703B1 (en) | 2000-11-13 | 2010-05-11 | Biosite, Inc. | Methods for monitoring the status of assays and immunoassays |
US6194222B1 (en) * | 1998-01-05 | 2001-02-27 | Biosite Diagnostics, Inc. | Methods for monitoring the status of assays and immunoassays |
US8062908B2 (en) * | 1999-03-29 | 2011-11-22 | Orasure Technologies, Inc. | Device for collection and assay of oral fluids |
ES2501241T3 (en) * | 1998-03-30 | 2014-10-01 | Orasure Technologies, Inc. | Collection device for oral fluid analysis |
US6303081B1 (en) * | 1998-03-30 | 2001-10-16 | Orasure Technologies, Inc. | Device for collection and assay of oral fluids |
US6183972B1 (en) * | 1998-07-27 | 2001-02-06 | Bayer Corporation | Method for the determination of analyte concentration in a lateral flow sandwich immunoassay exhibiting high-dose hook effect |
US7640083B2 (en) | 2002-11-22 | 2009-12-29 | Monroe David A | Record and playback system for aircraft |
US7449338B2 (en) * | 1998-10-02 | 2008-11-11 | Ischemia Technologies, Inc. | Tests for the rapid evaluation of ischemic states and kits |
US20030215359A1 (en) * | 1998-10-02 | 2003-11-20 | Ischemia Technologies, Inc. | Tests for the rapid evaluation of ischemic states and kits |
US7282369B2 (en) * | 1998-10-02 | 2007-10-16 | Ischemia Technologies, Inc. | Tests for the rapid evaluation of ischemic states and kits |
US20050142613A1 (en) * | 1998-10-02 | 2005-06-30 | David Bar-Or | Test for the rapid evaluation of ischemic states and kits |
US6475743B1 (en) | 1998-10-02 | 2002-11-05 | Ischemia Technologies, Inc. | Marker useful for detection and measurement of free radical damage and method |
US7070937B1 (en) | 1998-10-02 | 2006-07-04 | Ischemia Technologies, Inc. | Marker useful for detection and measurement of free radical damage and method |
AUPP713498A0 (en) * | 1998-11-17 | 1998-12-10 | Chandler, Howard Milne | A method of detecting blood |
US6136610A (en) | 1998-11-23 | 2000-10-24 | Praxsys Biosystems, Inc. | Method and apparatus for performing a lateral flow assay |
US6377894B1 (en) | 1998-11-30 | 2002-04-23 | Abbott Laboratories | Analyte test instrument having improved calibration and communication processes |
US6773671B1 (en) | 1998-11-30 | 2004-08-10 | Abbott Laboratories | Multichemistry measuring device and test strips |
US7148016B1 (en) * | 1999-01-14 | 2006-12-12 | Ca*Tx Inc. | Immunoassays to detect diseases or disease susceptibility traits |
FR2788856B1 (en) * | 1999-01-21 | 2001-07-13 | Adiatec Sa | TEST DEVICE AND METHOD FOR QUANTIFYING RESULTS OBTAINED BY IMMUNOCHROMATOGRAPHIC METHODS |
JP2000321277A (en) * | 1999-05-13 | 2000-11-24 | Matsushita Electric Ind Co Ltd | Chromatographic quantitative measuring apparatus |
JP4402263B2 (en) | 1999-06-21 | 2010-01-20 | パナソニック株式会社 | Chromatographic quantitative measurement device |
US20050103624A1 (en) | 1999-10-04 | 2005-05-19 | Bhullar Raghbir S. | Biosensor and method of making |
JP4223163B2 (en) * | 1999-10-25 | 2009-02-12 | パナソニック株式会社 | Immunochromatographic test strip and chromatographic analysis method |
US6509196B1 (en) | 2000-01-04 | 2003-01-21 | Response Biomedical Corp. | Compensation for non-specific signals in quantitative immunoassays |
DE10003734A1 (en) * | 2000-01-28 | 2001-08-02 | Bosch Gmbh Robert | Detection method and device |
US20020004246A1 (en) * | 2000-02-07 | 2002-01-10 | Daniels Robert H. | Immunochromatographic methods for detecting an analyte in a sample which employ semiconductor nanocrystals as detectable labels |
US6365417B1 (en) | 2000-02-09 | 2002-04-02 | A-Fem Medical Corporation | Collection device for lateral flow chromatography |
US6998273B1 (en) | 2000-02-09 | 2006-02-14 | A-Fem Medical Corporation | Collection device for lateral flow chromatography |
US6699722B2 (en) | 2000-04-14 | 2004-03-02 | A-Fem Medical Corporation | Positive detection lateral-flow apparatus and method for small and large analytes |
JP4562854B2 (en) | 2000-05-08 | 2010-10-13 | パナソニック株式会社 | Chromatographic measurement method |
JP3553045B2 (en) * | 2000-05-26 | 2004-08-11 | 松下電器産業株式会社 | Biosensor |
KR100513210B1 (en) | 2000-09-25 | 2005-09-08 | 마츠시타 덴끼 산교 가부시키가이샤 | Device for chromatographic quantitative measurement |
US6777198B2 (en) * | 2000-10-11 | 2004-08-17 | Pharmacia Diagnostics Ab | Assay method and kit therefor |
CN1182394C (en) * | 2000-12-26 | 2004-12-29 | 松下电器产业株式会社 | Specific bonding analysis method and specific bonding analysis device using it |
US7041787B2 (en) * | 2000-12-29 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases |
US6600057B2 (en) | 2000-12-29 | 2003-07-29 | Kimberly-Clark Worldwide, Inc. | Matrix metalloproteinase inhibitors |
US20030162236A1 (en) * | 2001-03-26 | 2003-08-28 | Response Biomedical Corporation | Compensation for variability in specific binding in quantitative assays |
US6770487B2 (en) * | 2001-05-01 | 2004-08-03 | Ischemia Technologies, Inc. | Bar code readable diagnostic strip test |
AU2003270548B2 (en) | 2002-09-09 | 2008-09-25 | Arbor Vita Corporation | Methods of diagnosing cervical cancer |
KR100550707B1 (en) * | 2001-08-09 | 2006-02-08 | 마츠시타 덴끼 산교 가부시키가이샤 | Biosensors and measurement method |
US7537731B2 (en) | 2001-10-19 | 2009-05-26 | Panasonic Corporation | Specific binding analysis device |
US7102752B2 (en) * | 2001-12-11 | 2006-09-05 | Kimberly-Clark Worldwide, Inc. | Systems to view and analyze the results from diffraction-based diagnostics |
US20030119073A1 (en) * | 2001-12-21 | 2003-06-26 | Stephen Quirk | Sensors and methods of detection for proteinase enzymes |
US6837171B1 (en) | 2002-04-29 | 2005-01-04 | Palmer/Snyder Furniture Company | Lightweight table with unitized table top |
US20030119203A1 (en) | 2001-12-24 | 2003-06-26 | Kimberly-Clark Worldwide, Inc. | Lateral flow assay devices and methods for conducting assays |
US8367013B2 (en) | 2001-12-24 | 2013-02-05 | Kimberly-Clark Worldwide, Inc. | Reading device, method, and system for conducting lateral flow assays |
US7175992B2 (en) * | 2002-04-10 | 2007-02-13 | Response Biomedical Corporation | Sensitive immunochromatographic assay |
CA2480833C (en) * | 2002-04-10 | 2011-09-13 | Response Biomedical Corporation | Sensitive immunochromatographic assay |
US7771922B2 (en) | 2002-05-03 | 2010-08-10 | Kimberly-Clark Worldwide, Inc. | Biomolecule diagnostic device |
US7214530B2 (en) | 2002-05-03 | 2007-05-08 | Kimberly-Clark Worldwide, Inc. | Biomolecule diagnostic devices and method for producing biomolecule diagnostic devices |
US7108993B2 (en) * | 2002-07-19 | 2006-09-19 | Bayer Healthcare Llc | Use of dual conjugated labels in the elimination of serum interference in immunochromatographic assays |
US20040018576A1 (en) * | 2002-07-24 | 2004-01-29 | Dematteo Todd M. | Bence Jones protein testing cassette |
US7285424B2 (en) | 2002-08-27 | 2007-10-23 | Kimberly-Clark Worldwide, Inc. | Membrane-based assay devices |
US7247500B2 (en) | 2002-12-19 | 2007-07-24 | Kimberly-Clark Worldwide, Inc. | Reduction of the hook effect in membrane-based assay devices |
FI20030463A0 (en) * | 2003-03-28 | 2003-03-28 | Ani Biotech Oy | Multichannel test instrument, method of its manufacture and its use |
US20040197819A1 (en) | 2003-04-03 | 2004-10-07 | Kimberly-Clark Worldwide, Inc. | Assay devices that utilize hollow particles |
US7851209B2 (en) | 2003-04-03 | 2010-12-14 | Kimberly-Clark Worldwide, Inc. | Reduction of the hook effect in assay devices |
US7074194B2 (en) * | 2003-05-19 | 2006-07-11 | Ischemia Technologies, Inc. | Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin |
US8101429B2 (en) * | 2003-06-03 | 2012-01-24 | Siemens Healthcare Diagnostics Inc. | Native analyte as a reference in lateral flow assays |
US7452457B2 (en) | 2003-06-20 | 2008-11-18 | Roche Diagnostics Operations, Inc. | System and method for analyte measurement using dose sufficiency electrodes |
US8148164B2 (en) | 2003-06-20 | 2012-04-03 | Roche Diagnostics Operations, Inc. | System and method for determining the concentration of an analyte in a sample fluid |
US8058077B2 (en) | 2003-06-20 | 2011-11-15 | Roche Diagnostics Operations, Inc. | Method for coding information on a biosensor test strip |
US7488601B2 (en) | 2003-06-20 | 2009-02-10 | Roche Diagnostic Operations, Inc. | System and method for determining an abused sensor during analyte measurement |
US7718439B2 (en) | 2003-06-20 | 2010-05-18 | Roche Diagnostics Operations, Inc. | System and method for coding information on a biosensor test strip |
US8071030B2 (en) | 2003-06-20 | 2011-12-06 | Roche Diagnostics Operations, Inc. | Test strip with flared sample receiving chamber |
US8206565B2 (en) | 2003-06-20 | 2012-06-26 | Roche Diagnostics Operation, Inc. | System and method for coding information on a biosensor test strip |
US7645373B2 (en) | 2003-06-20 | 2010-01-12 | Roche Diagnostic Operations, Inc. | System and method for coding information on a biosensor test strip |
PL1639354T3 (en) | 2003-06-20 | 2018-11-30 | F.Hoffmann-La Roche Ag | Test strip with slot vent opening |
US8679853B2 (en) | 2003-06-20 | 2014-03-25 | Roche Diagnostics Operations, Inc. | Biosensor with laser-sealed capillary space and method of making |
US7645421B2 (en) | 2003-06-20 | 2010-01-12 | Roche Diagnostics Operations, Inc. | System and method for coding information on a biosensor test strip |
CA2510277C (en) | 2003-09-23 | 2012-07-24 | Epinex Diagnostics, Inc. | Rapid test for glycated albumin |
US20050112703A1 (en) | 2003-11-21 | 2005-05-26 | Kimberly-Clark Worldwide, Inc. | Membrane-based lateral flow assay devices that utilize phosphorescent detection |
US7713748B2 (en) | 2003-11-21 | 2010-05-11 | Kimberly-Clark Worldwide, Inc. | Method of reducing the sensitivity of assay devices |
US7943395B2 (en) | 2003-11-21 | 2011-05-17 | Kimberly-Clark Worldwide, Inc. | Extension of the dynamic detection range of assay devices |
US7943089B2 (en) | 2003-12-19 | 2011-05-17 | Kimberly-Clark Worldwide, Inc. | Laminated assay devices |
WO2005078118A1 (en) | 2004-02-06 | 2005-08-25 | Bayer Healthcare Llc | Oxidizable species as an internal reference for biosensors and method of use |
EP1733233B1 (en) * | 2004-03-30 | 2012-12-12 | GE Healthcare Bio-Sciences Corp. | Lateral flow format, materials and methods |
US7319032B2 (en) * | 2004-04-22 | 2008-01-15 | Medtox | Non-sugar sweeteners for use in test devices |
DE102004023402A1 (en) * | 2004-05-12 | 2005-12-08 | Roche Diagnostics Gmbh | Method for increasing the dynamic measuring range of, in particular immunological test elements based on specific binding reactions |
US7569126B2 (en) | 2004-06-18 | 2009-08-04 | Roche Diagnostics Operations, Inc. | System and method for quality assurance of a biosensor test strip |
US7521226B2 (en) | 2004-06-30 | 2009-04-21 | Kimberly-Clark Worldwide, Inc. | One-step enzymatic and amine detection technique |
US7442557B1 (en) | 2004-10-22 | 2008-10-28 | Idexx Laboratories, Inc. | Bi-directional flow assay device with reagent bridge |
EP1844332A1 (en) * | 2005-02-04 | 2007-10-17 | Diagnostica Stago | Immunochromatographic method for the quantitative measurement of analytes in a liquid sample |
FR2881828B1 (en) * | 2005-02-04 | 2007-11-30 | Diagnostica Stago Soc Par Acti | METHOD OF QUANTITATIVE MEASUREMENT BY IMMUNOCHROMATOGRAPHY, ANALYTES IN A LIQUID SAMPLE |
US8709792B2 (en) * | 2005-02-18 | 2014-04-29 | Charm Sciences, Inc. | Lateral flow test kit and method for detecting an analyte |
US7785899B2 (en) * | 2005-02-18 | 2010-08-31 | Charm Sciences, Inc. | Lateral flow test kit and method for detecting an analyte |
US20060246513A1 (en) * | 2005-05-02 | 2006-11-02 | Bohannon Robert C | Method and device to detect the presence of analytes in a sample |
WO2007013915A1 (en) | 2005-07-20 | 2007-02-01 | Bayer Healthcare Llc | Gated amperometry |
CN101273266B (en) | 2005-09-30 | 2012-08-22 | 拜尔健康护理有限责任公司 | Gated voltammetry |
US7816122B2 (en) * | 2005-10-18 | 2010-10-19 | Idexx Laboratories, Inc. | Lateral flow device with onboard reagents |
US7935538B2 (en) | 2006-12-15 | 2011-05-03 | Kimberly-Clark Worldwide, Inc. | Indicator immobilization on assay devices |
WO2008086137A1 (en) * | 2007-01-08 | 2008-07-17 | 3M Innovative Properties Company | Device for the qualification of cooking oils, and methods |
EP2132571B1 (en) * | 2007-02-26 | 2014-09-03 | Response Biomedical Corporation | Comparative multiple analyte assay |
US8865454B2 (en) * | 2007-03-22 | 2014-10-21 | Scandinavian Micro Biodevices Aps | Flow through system, flow through device and a method of performing a test |
WO2009076302A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Healthcare Llc | Control markers for auto-detection of control solution and methods of use |
US8257976B2 (en) * | 2008-03-04 | 2012-09-04 | 3M Innovative Properties Company | Monitoring of frying oil quality using combined optical interrogation methods and devices |
KR20100131464A (en) * | 2008-03-04 | 2010-12-15 | 쓰리엠 이노베이티브 프로퍼티즈 캄파니 | Methods and devices for monitoring of frying oil quality |
WO2009112038A2 (en) | 2008-03-14 | 2009-09-17 | Scandinavian Micro Biodevices Aps | A microfluidic system and a method of performing a test |
US8962260B2 (en) | 2008-05-20 | 2015-02-24 | Rapid Pathogen Screening, Inc. | Method and device for combined detection of viral and bacterial infections |
US20130196310A1 (en) | 2008-05-20 | 2013-08-01 | Rapid Pathogen Screening, Inc. | Method and Device for Combined Detection of Viral and Bacterial Infections |
US9910036B2 (en) | 2008-05-20 | 2018-03-06 | Rapid Pathogen Screening, Inc. | Method and device for combined detection of viral and bacterial infections |
WO2009154534A1 (en) * | 2008-06-18 | 2009-12-23 | Jan Carlsson | Determination of distribution |
EP2307141B1 (en) | 2008-07-29 | 2019-02-20 | Scandinavian Micro Biodevices ApS | A microfluidic device |
US8446463B2 (en) | 2008-08-22 | 2013-05-21 | Genprime, Inc. | Apparatus, method and article to perform assays using assay strips |
EP2348316B1 (en) | 2008-10-09 | 2013-08-28 | Actherm Inc. | A method for testing a liquid |
RU2477754C2 (en) | 2008-10-17 | 2013-03-20 | Актерм Инк. | Indicator strip for liquid and method |
WO2010043075A1 (en) | 2008-10-17 | 2010-04-22 | 红电医学科技股份有限公司 | Liquid test strip and the method |
CA2755347A1 (en) | 2009-03-23 | 2010-09-30 | Actherm Inc. | Analytical strip and the manufacturing method thereof |
CN102414561A (en) * | 2009-04-28 | 2012-04-11 | 创新实验室技术公司 | Lateral-flow immuno-chromatographic assay devices |
US9335290B2 (en) | 2011-12-23 | 2016-05-10 | Abbott Point Of Care, Inc. | Integrated test device for optical and electrochemical assays |
WO2013096817A2 (en) | 2011-12-23 | 2013-06-27 | Abbott Point Of Care Inc | Integrated test device for optical detection of microarrays |
US9377475B2 (en) | 2011-12-23 | 2016-06-28 | Abbott Point Of Care Inc. | Optical assay device with pneumatic sample actuation |
US9194859B2 (en) | 2011-12-23 | 2015-11-24 | Abbott Point Of Care Inc. | Reader devices for optical and electrochemical test devices |
US20130280696A1 (en) | 2012-04-23 | 2013-10-24 | Elliott Millenson | Devices and methods for detecting analyte in bodily fluid |
US9528941B2 (en) | 2012-08-08 | 2016-12-27 | Scanadu Incorporated | Method and apparatus for determining analyte concentration by quantifying and interpreting color information captured in a continuous or periodic manner |
WO2014025415A2 (en) | 2012-08-08 | 2014-02-13 | Scanadu Incorporated | Method and apparatus for performing and quantifying color changes induced by specific concentrations of biological analytes in an automatically calibrated environment |
US9285323B2 (en) | 2012-08-08 | 2016-03-15 | Scanadu Incorporated | Quantifying color changes of chemical test pads induced concentrations of biological analytes under different lighting conditions |
US9360479B2 (en) | 2012-11-15 | 2016-06-07 | Daniel Wang | Rapid lateral flow assay method for low quantity liquid or dry samples |
BR112015011040A2 (en) | 2012-11-15 | 2017-07-11 | Ortho Clinical Diagnostics Inc | test calibration using reaction time |
JP6417725B2 (en) * | 2014-06-06 | 2018-11-07 | 凸版印刷株式会社 | Analyte detection method |
WO2016025935A2 (en) | 2014-08-15 | 2016-02-18 | Scanadu Incorporated | Precision luxmeter methods for digital cameras to quantify colors in uncontrolled lighting environments |
US10808287B2 (en) | 2015-10-23 | 2020-10-20 | Rapid Pathogen Screening, Inc. | Methods and devices for accurate diagnosis of infections |
US10576475B2 (en) | 2016-09-15 | 2020-03-03 | Genprime, Inc. | Diagnostic assay strip cassette |
CA3116909A1 (en) | 2018-10-24 | 2020-04-30 | Orasure Technologies, Inc. | Lateral flow assays for differential isotype detection |
EP3980182A1 (en) | 2019-06-04 | 2022-04-13 | Abbott Toxicology Limited | Fluid specimen testing |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE388694B (en) * | 1975-01-27 | 1976-10-11 | Kabi Ab | WAY TO PROVIDE AN ANTIGEN EXV IN SAMPLES OF BODY WHEATS, USING POROST BERAR MATERIAL BONDED OR ADSORBING ANTIBODIES |
NL7807532A (en) * | 1978-07-13 | 1980-01-15 | Akzo Nv | METAL IMMUNO TEST. |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4446232A (en) * | 1981-10-13 | 1984-05-01 | Liotta Lance A | Enzyme immunoassay with two-zoned device having bound antigens |
US4868108A (en) * | 1985-12-12 | 1989-09-19 | Hygeia Sciences, Incorporated | Multiple-antibody detection of antigen |
US4772561A (en) * | 1985-12-23 | 1988-09-20 | Miles Inc. | Test device and method of determining concentration of a sample component |
EP0231951B1 (en) * | 1986-02-07 | 1993-06-09 | Fuji Photo Film Co., Ltd. | Chemical analysis apparatus |
DE560410T1 (en) * | 1987-04-27 | 2001-12-20 | Unilever Nv | Test device for carrying out specific binding tests. |
US4943522A (en) * | 1987-06-01 | 1990-07-24 | Quidel | Lateral flow, non-bibulous membrane assay protocols |
US5120643A (en) * | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
US4833088A (en) * | 1987-09-25 | 1989-05-23 | Miles Inc. | Reagent strip handling mechanism |
US4859612A (en) * | 1987-10-07 | 1989-08-22 | Hygeia Sciences, Inc. | Metal sol capture immunoassay procedure, kit for use therewith and captured metal containing composite |
DE3826057A1 (en) * | 1988-07-30 | 1990-02-01 | Boehringer Mannheim Gmbh | TEST TESTER FOR THE ANALYTICAL DETERMINATION OF AN INGREDIENT OF A LIQUID SAMPLE |
US5141850A (en) * | 1990-02-07 | 1992-08-25 | Hygeia Sciences, Inc. | Porous strip form assay device method |
US5308775A (en) * | 1992-09-15 | 1994-05-03 | Abbott Laboratories | Assay devices for concurrently detecting an analyte and confirming the test result |
-
1995
- 1995-01-30 US US08/380,119 patent/US5569608A/en not_active Expired - Lifetime
-
1996
- 1996-01-10 CA CA002166913A patent/CA2166913A1/en not_active Abandoned
- 1996-01-17 EP EP96100599A patent/EP0724157A2/en not_active Withdrawn
- 1996-01-17 ZA ZA96357A patent/ZA96357B/en unknown
- 1996-01-27 KR KR1019960001777A patent/KR960029790A/en not_active Application Discontinuation
- 1996-01-29 CN CN96104311A patent/CN1146557A/en active Pending
- 1996-01-29 AU AU42226/96A patent/AU4222696A/en not_active Abandoned
- 1996-01-29 JP JP8013273A patent/JPH08240591A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US5569608A (en) | 1996-10-29 |
EP0724157A2 (en) | 1996-07-31 |
AU4222696A (en) | 1996-08-08 |
ZA96357B (en) | 1996-08-01 |
JPH08240591A (en) | 1996-09-17 |
KR960029790A (en) | 1996-08-17 |
CN1146557A (en) | 1997-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5569608A (en) | Quantitative detection of analytes on immunochromatographic strips | |
EP1634078B1 (en) | Native analyte as reference in lateral flow assays | |
US10429382B2 (en) | Immunological test element with control zone for identifying hook effect | |
US6924153B1 (en) | Quantitative lateral flow assays and devices | |
US6436721B1 (en) | Device and method for obtaining clinically significant analyte ratios | |
EP0138826B1 (en) | Detection of human chorionic gonadotropin | |
EP0335244B1 (en) | Solid-phase analytical device and method for using same | |
US20100210038A1 (en) | Dry reagent particle assay and device having multiple test zones and method therefor | |
JPH04230857A (en) | Method and apparatus for bonding assay | |
US20060246522A1 (en) | C-reactive protein immunoassay and method | |
US9201065B2 (en) | Agglutination assay | |
US8101429B2 (en) | Native analyte as a reference in lateral flow assays | |
EP0902287B1 (en) | Method and test strip for reducing urea effect of immunochromatographic assays using urine samples | |
EP1540343B1 (en) | Method for the elimination of interferences in immunochromatographic assays | |
CA2198948A1 (en) | Quantitative detection of analytes on immunochromatographic strips |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 19990111 |